Takeda is sued for delaying the listing of Amitiza's generic drug

CompilationFan Dongdong

A few days ago, foreign media reported that according to the latest class-action lawsuit, the patent agreement reached between Takeda and Endo’s Par Pharmaceuticals delayed the launch of Takeda’s constipation drug Amitiza, suspected of violating the antitrust law, causing The patient's medical expenses exceeded hundreds of millions of yuan

For many years, brand-name drugmakers have been reconciling with generic drug companies to expand and extend market exclusivity

The plaintiff claimed in the Federal Court of Massachusetts in the United States that the transaction allowed the two companies to "maintain their monopoly on Amitiza" and effectively delayed the competition for the generic drug for several years

Previously, Takeda obtained the commercial rights to Amitiza through a license agreement with Sucampo Pharmaceuticals, which is now part of Mallinckrodt Pharmaceuticals

At that time, Takeda quickly filed a lawsuit against the generic drug company, accusing it of infringement of 6 patents of the original drug

According to FDA regulations, the first company to apply for a generic generic drug has six months of exclusivity.

Although Amitiza is not the best-selling drug in the industry, the drug has always been an important asset of Takeda

In recent years, it is not uncommon for major pharmaceutical companies to make settlement payments for the postponement of the listing of generic drugs, and they have gradually attracted the attention of regulatory authorities

In addition, the US Federal Trade Commission is suing Endo for another deferred payment agreement

Reference source: Takeda, Endo reaped'many hundreds of millions' through Amitiza pay-for-delay deal, lawsuit claims